menu
    • menu

    Company profile for ALX Oncology

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a first-in-class fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to enhance the efficacy of antibody-b...
    ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a first-in-class fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to enhance the efficacy of antibody-based therapies and is in clinical development for a broad range of tumor types.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ALX OncologyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    866 Malcolm Road, Suite 100 Burlingame, CA 94010
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://alxoncology.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/alexo-therapeutics
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ALX Oncology Reports Positive Phase 2 Trial Results
    ALX Oncology Reports Positive Phase 2 Trial Results

    07 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/07/3201128/0/en/ALX-Oncology-Announces-Positive-Results-from-Ongoing-Investigator-Sponsored-Phase-2-Trial-Evaluating-Evorpacept-in-Combination-with-Standard-of-Care-Treatment-in-Patients-with-Indo.html

    GLOBENEWSWIRE
    07 Dec 2025
    Share Share
    ALX Oncology To Present At Upcoming Investor Conferences
    ALX Oncology To Present At Upcoming Investor Conferences

    18 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/18/3190290/0/en/ALX-Oncology-to-Present-at-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    18 Nov 2025
    Share Share
    ALX Oncology Reveals Q3 2025 Financials & Corporate Update
    ALX Oncology Reveals Q3 2025 Financials & Corporate Update

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183623/0/en/ALX-Oncology-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    ALX Oncology to Unveil Q3 2025 Financial & Evorpacept Cd47 Update
    ALX Oncology to Unveil Q3 2025 Financial & Evorpacept Cd47 Update

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3177412/0/en/ALX-Oncology-to-Report-Third-Quarter-2025-Financial-Results-and-Pipeline-Progress-Including-Evorpacept-CD47-Biomarker-Data-to-be-Presented-at-Upcoming-SITC-Annual-Meeting.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share
    ALX Oncology Unveils ALX2004, Preclinical Data At AACR-NCI-EORTC
    ALX Oncology Unveils ALX2004, Preclinical Data At AACR-NCI-EORTC

    23 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/23/3172323/0/en/ALX-Oncology-Announces-Preclinical-Data-and-Phase-1-Trial-in-Progress-Presentations-of-ALX2004-a-Novel-EGFR-Targeted-ADC-at-2025-AACR-NCI-EORTC-Conference.html

    GLOBENEWSWIRE
    23 Oct 2025
    Share Share
    ALX Oncology Showcases CD47 As Biomarker In HER2+ Gastric Cancer
    ALX Oncology Showcases CD47 As Biomarker In HER2+ Gastric Cancer

    03 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/03/3160981/0/en/ALX-Oncology-to-Present-Updated-Data-from-Phase-2-ASPEN-06-Trial-Highlighting-CD47-Expression-as-a-Predictive-Biomarker-in-HER2-Gastric-Cancer-at-40th-Society-for-Immunotherapy-of-.html

    GLOBENEWSWIRE
    03 Oct 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search